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Purpose. To compare the functional and clinical outcomes of the iris-claw intraocular lens (IOL) placed on the anterior versus
posterior surface of the iris. Patients and Methods. A multicenter, retrospective study. Data on eyes that underwent anterior or
retropupillary iris-claw IOL implantation because of inadequate capsular support secondary to complicated cataract surgery,
trauma, and dislocated/opaciﬁed IOLs since January 2015 were analyzed. For study inclusion, evaluation results had to be available
in the medical records both preoperatively and at 1 and 12 months after implantation. *e following parameters were compared
between the groups: best-corrected distance visual acuity (BCDVA), spherical and cylindrical refractive error, endothelial cell
density (ECD), central macular thickness (CMT), and percentage and type of postoperative complications. Results. In total, 60 eyes
of 60 patients aged 73 ± 13 years were included: 28 eyes (47%) involved anterior, and 32 eyes (53%) retropupillary, iris-claw IOL
ﬁxations. Preoperatively, the groups were similar in all parameters except for a signiﬁcantly higher proportion of retropupillary
ﬁxations in patients who had previously experienced a closed-globe trauma (p � 0.03). *e groups showed comparable im-
provements in BCDVA after surgery (ﬁnal BCDVA: 0.34 ± 0.45 vs. 0.37 ± 0.50 logMAR in the anterior and retropupillary
placement groups, respectively). During follow-up, no group diﬀerence was observed in refractive error or CMT. Both groups
experienced similarly marked ECD loss and showed similar incidence of postoperative complications, with cystoidmacular edema
being the most common complication. Multivariable linear regression showed that BCDVA at 1 month was the best predictor of
the ﬁnal BCDVA. Conclusions. Anterior chamber and posterior chamber iris-claw IOL ﬁxations proved equally eﬀective and safe
for aphakic correction in eyes with inadequate capsular support.
1. Introduction
Management of intraocular lens (IOL) implantation in eyes
with inadequate capsular support is challenging. Inadequate
capsular support precluding the availability of the natural
bag or of the sulcus can result from complicated cataract
surgery, luxation of the crystalline lens, or from dislocation
or opaciﬁcation of a previous conventional IOL. Various
methods of surgical correction have been described,
including placement of specialized IOLs supported by the
anterior chamber (AC) angle or iris or of scleral-ﬁxated IOLs
[1–3]. Iris-ﬁxated IOLs secured to the anterior surface of the
iris using a claw-shaped haptic device were initially used for
correction of aphakia [4]. Although this type of IOL was
used extensively in the past, it is no longer recommended
because of relatively high complication rates and suboptimal
visual outcomes [5, 6]. However, anterior iris-claw IOLs
have since undergone signiﬁcant design changes, including
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vault modiﬁcations, which have enabled their use for re-
fractive correction of high myopia in phakic eyes. *ese
advances, along with the ease of surgical insertion, have led
to the reintroduction of anterior iris-claw IOLs for cor-
rection of aphakia without a capsular support [7, 8]. Iris-
claw IOLs can also be securely ﬁxed to the posterior surface
of the iris, to maintain the physiological position of the
diaphragm in the posterior chamber (PC) of the eye and thus
reduce the potential for the complications associated with
AC IOLs. Many investigators have reported relatively large
series, both prospective and retrospective, demonstrating
the midterm safety and eﬃcacy of this procedure [9–12].
Both AC and PC iris-claw IOLs were also found to be safe
and eﬀective for visual rehabilitation in young patients
[13, 14]. Iris-claw ﬁxation, both anterior and retropupillary,
is technically less demanding than scleral ﬁxation and is now
used in routine practice by many surgeons. Only one study
has prospectively compared the visual outcomes between the
anterior and retropupillary approaches for ﬁxation of iris-
claw IOLs, wherein no diﬀerence was noted [15]. However,
the study was limited by a small sample size and short
follow-up. *e present study aimed to supplement the
available data by retrospectively investigating long-term
safety and visual outcomes in a larger cohort of eyes
implanted with either AC or PC iris-claw IOLs.
2. Methods
*is was a three-center retrospective study of patients who
received AC or PC iris-claw IOL implants from January
2015. Informed consent was obtained from all patients, and
all procedures adhered to the tenets of the Declaration of
Helsinki. *e inclusion criteria were (a) uneventful im-
plantation (i.e., absence of intraoperative complications such
as iridodialysis, iris bleeding, or intraoperative disen-
clavation) of an Artisan® (Ophtec, Groningen, *e Neth-erlands) iris-claw IOL, inserted due to a lack of capsule
support; and (b) medical records showing the results of
complete eye examinations (as detailed below), pre-
operatively and at 1 and 12 months after surgery. Windows
of ±1 and ±4 weeks were allowed for the evaluations at 1 and
12 months, respectively. *e exclusion criterion was any
severe media opacity precluding examination of the ocular
structures. Complete examination results had to be available
within the medical records, including an up-to-date medical
history; refraction assessment; best-corrected distance visual
acuity (BCDVA; assessed by the standard Early Treatment of
Diabetic Retinopathy Study chart); slit lamp examination,
fundus evaluation, and intraocular pressure (IOP) results;
corneal endothelial cell density (ECD) count; and macular
optical coherence tomography (OCT) data. Included eyes
(one per patient) were divided into two groups according to
the implant position: anterior (group A) or posterior (group
B) (Figure 1). *e following parameters were compared
between the groups: BCDVA (given by the logarithm of the
minimum angle of resolution, logMAR), the spherical and
cylindrical refractive error (considered separately after
conversion to positive cylinders), ECD, central macular
thickness (CMT), and the percentage and type of
postoperative complications and/or anomalies. *ese data
were collected by an experienced clinician; either an oph-
thalmologist or a certiﬁed ophthalmic technician. ECD was
expressed as the number of cells per mm2 and was measured
in all patients with a specular microscope (SP-2000P; Topcon
America, Paramus, NJ, USA) using the “center-dot” cell
counting method. CMTwas assessed in all patients, according
to the central subﬁeld thickness, via “macular cube 512 × 128”
OCT scans performed with the Cirrus HD-OCT 4000 in-
strument (Carl Zeiss Meditec, Dublin, CA, USA).
2.1. Surgical Techniques. An Artisan® (Ophtec) IOL wasused during the surgery; Artisan® is a rigid poly(methylmethacrylate) IOL 8.5mm in length and with a maximum
height of 1.04mm and an optical zone width of 5.4mm.*e
IOL power was calculated using the SRK/Tformula.*e IOL
targeted emmetropia in all patients. An A-constant of 115.0,
as per the manufacturer’s recommendation, was used for
anterior implantation, while an A-constant of 116.5 was used
for retropupillary ﬁxation. Anesthesia was either general or
peribulbar. Whenever indicated, the surgical procedure was
combined with lens/IOL removal or pars plana vitrectomy
(PPV). Surgeons selected either AC or PC placement
depending on their individual experience and the charac-
teristics of the speciﬁc surgical procedure, in particular the
presence/necessity of a vitreous access which could allow to
handle the implant even from behind by a vitreous pick as
a rescue measure in the case of unsuitable retropupillary iris
hooking. *e same standardized surgical technique was
applied in both procedures. Two side ports were made at the
3 and 9 o’clock positions. Anterior vitrectomy was per-
formed as required. Miosis was achieved using intracameral
carbachol, and a viscoelastic agent was injected into the
anterior chamber. A 5.5mm superior limbal corneal incision
was made, and the IOL (with the vault facing up and down
for the anterior clawed lens and retropupillary lens, re-
spectively) was inserted into the AC. *e IOL was rotated
such that the haptics were lined at the 3 and 9 o’clock
positions. *ereafter, the IOL optic plate was held in place
with Artisan lens forceps (Ophtec); for AC implantation, iris
was enclavated at midperiphery between claw haptics using
a special enclavation microspatula introduced through the
ipsilateral side port. For retropupillary ﬁxation, after posi-
tioning one haptic of the IOL behind the iris, it was
enclavated using the microspatula, followed by enclavation
of the other haptic. Superior peripheral iridectomy was
performed only for AC implantations. Finally, the corneal
incision was sutured using noncontinuous 10–0 non-
absorbable nylon sutures, which were removed at a mini-
mum of 6 weeks after surgery. Postoperative therapy
included antibiotic and nonsteroidal anti-inﬂammatory eye
drops for 1 month.
2.2. Statistical Analysis. Continuous variables were
expressed as means ± standard deviation (SD) or as me-
dians with the interquartile range (IQR), while categorical
variables were presented as proportions. Diﬀerences be-
tween groups in the preoperative characteristics (Table 1)
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and in postoperative complications (Table 2) were analyzed
using Student’s t-test for continuous variables and the chi-
squared test or Fisher’s exact test for categorical variables.
*e study outcomes BCDVA, CMT, and ECD loss were
analyzed with a two-way ANOVA model (main eﬀect:
Group and Time) with interaction term (Group ∗ Time).
*e program R cran, ver. 3.4.0 was used to perform the
analyses. For post hoc analysis, we used a Fisher’s Least
Signiﬁcant Diﬀerence (LSD) test (95% family-wise conﬁ-
dence level). Univariate and multivariable linear regression
analyses were performed to evaluate factors inﬂuencing the
ﬁnal BCDVA. Covariates signiﬁcant at p< 0.1 in univariate
analyses were included in the multivariable analyses, as
were those showing variance inﬂation ≤10 or having
(a) (b)
Figure 1: Slit-lamp photographs of iris-claw IOLs implanted in the anterior chamber (a) and in the posterior chamber (b).
Table 1: Demographic and baseline characteristics in the two groups.
Patients’ characteristics Group A (n � 28) Group B (n � 32) p value
Age, years 72.7 ± 13.5 73.8 ± 13.4 N.S.
Males, n (%) 20 (71%) 21 (66%) N.S.
Right eyes, n (%) 17 (61%) 14 (44%) N.S.
IOP, mmHg 15.7 ± 5.1 16.2 ± 4.3 N.S.
Preexistent corneal pathology, n (%) 3 (11%) 4 (12.5%) N.S.
Preexistent macular pathology, n (%) 2 (7%) 2 (6%) N.S.
Preexistent retinal pathology, n (%) 8 (29%) 11 (34%) N.S.
Prior closed-globe trauma, n (%) 3 (11%) 11 (34%) 0.03
Prior open-globe trauma, n (%) 2 (7%) 5 (16%) N.S.
Prior cataract surgery, n (%) 18 (64%) 17 (53%) N.S.
Preoperative lens status
Subluxated cataract, n (%) 5 (18%) 4 (12.5%)
N.S.
Dislocated nucleus, n (%) 5 (18%) 11 (34%)
Subluxated IOL, n (%) 6 (21%) 5 (16%)
Dislocated IOL, n (%) 1 (3.5%) 4 (12.5%)
Opaciﬁed IOL, n (%) 1 (3.5%) 0 (0%)
Aphakia, n (%) 10 (36%) 8 (25%)
Continuous variables are presented as means ± standard deviation. n: number; IOP: intraocular pressure; IOL: intraocular lens; N.S.: not signiﬁcant, p> 0.05.
Table 2: Cumulative incidence of postoperative complications in the two groups over 12 months after surgery.
Postoperative complication Group A Group B p value
Cystoid macular edema (%) 33 25 N.S.
Transiently raised IOP (%) 32 22 N.S.
Pseudophakic bullous keratopathy (%) 7 16 N.S.
Epiretinal membrane (%) 7 16 N.S.
Persistent IOP elevation (%) 18 3 N.S. (0.08)
IOL tilting or decentration (%) 11 3 N.S.
Iritis (%) 7 3 N.S.
Retinal detachment (%) 0 3 N.S.
Endophthalmitis (%) 0 0
IOL disenclavation, subluxation, or dislocation (%) 0 0
IOP: intraocular pressure; IOL: intraocular lens; N.S.: not signiﬁcant, p> 0.05.
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clinical relevance for the study (e.g., anterior vs. posterior
implantation). Best-ﬁt regression models were created
based on stepwise forward and backward methods. Cor-
relations between continuous variables are described by
LOWESS curves and Pearson’s correlation coeﬃcients. All
data were entered into Excel software (Microsoft Corp.,
Redmond, WA, USA) and analyzed using Stata software
(ver. 12.0; Stata Corp., Fort Worth, TX, USA). A p value of<0.05 was considered statistically signiﬁcant.
3. Results
Sixty eyes of sixty subjects (41 males and 19 females; mean
age, 73 ± 13 years) were included in the study. In total, 28
eyes (47%) with anterior iris-claw IOL ﬁxation were assigned
to group A, and 32 eyes (53%) with retropupillary ﬁxation
were assigned to group B. *e demographic and pre-
operative characteristics of the two groups are listed in
Table 1. *e groups were similar on all parameters, except
for a signiﬁcantly higher proportion of retropupillary ﬁxa-
tions in patients who had previously experienced a closed-
globe trauma (p � 0.03). Iris-claw IOL ﬁxation directly
followed lens removal in 25 eyes (42% of cases): the in-
dications were complicated cataract surgery in 15 patients and
lens dislocation because of trauma or pseudoexfoliative
syndrome in 10 patients; the remaining cases were secondary
implantations in aphakic eyes (18 cases, 30%) or conventional
IOL exchanges because of subluxation/dislocation or opaci-
ﬁcation (17 cases, 28%). Overall, PPV was performed in
combination with iris-claw IOL ﬁxation in 38 eyes (no dif-
ference in the rate of performance between the two groups).
According to the within-group analysis shown in Table 3,
BCDVA signiﬁcantly improved after surgery in both groups,
without signiﬁcant diﬀerence between the two groups. *e
post hoc analysis showed that the improvement was
statistically signiﬁcant in the time intervals: preop.: 1 month,
and preop.: 12 months. At 12 months, spherical and cylin-
drical refractive errors were also comparable between the two
groups. Preoperative OCTdata were available, and of suitable
quality, in 48 patients (21 in groupA and 27 in group B): CMT
data and the incidence of CME referred to this subgroup of
patients accordingly; the CMT did not signiﬁcantly change
after surgery in either group (Table 3). To determine the
ECDs, ten eyes (seven in group B) were excluded from the
analysis because of a prior corneal surgery (corneal trans-
plantation or corneal wound suture) or because they de-
veloped corneal decompensation during the follow-up.
Compared with the preoperative assessments, the ECDs were
signiﬁcantly reduced in both groups after surgery, without
a signiﬁcant intergroup diﬀerence (Table 3); at the 1-month
postoperative visit, the median losses were 194 cells/mm2
(IQR: 65–554 cells/mm2) and 203 cells/mm2 (IQR: 93–755
cells/mm2) in groups A and B, respectively, with no in-
tergroup diﬀerence (p � 0.51). *e ECD showed a further
decrease at the ﬁnal evaluation; the median losses between 1
and 12 months were 90 cells/mm2 (IQR: 7–221 cells/mm2)
and 109 cells/mm2 (IQR: 15–209 cells/mm2) in groups A and
B, respectively, with no intergroup diﬀerence (p � 0.89)
(Figure 2). Again, the post hoc analysis showed that the loss
was statistically signiﬁcant in the time intervals: preop.: 1
month, and preop.: 12 months. *e most frequent compli-
cations in both groups throughout the postoperative follow-
up were cystoid macular edema (CME) (Figure 3) and
transiently increased IOP. CME was detected in 5 subjects at
the 1-month visit (1 patient in group A and 4 in group B). At
the 1-year visit, CMEwas detected in 10 subjects (6 in groupA
and 4 in group B), with one patient in group B showing CME
at both the postoperative visits. *e cumulative incidence of
CME over 12 months after surgery was not signiﬁcantly
diﬀerent between the two groups. CME occurred in 6 patients
Table 3: Outcomes variables at diﬀerent time points in the two groups.
Group A (n � 28) Group B (n � 32) p value
Preop. BCDVA (logMAR) 0.66 ± 0.60 0.80 ± 0.66
N.S.1-month postop. BCDVA (logMAR) 0.35 ± 0.30 0.50 ± 0.50
1-year postop. BCDVA (logMAR) 0.34 ± 0.45 0.37 ± 0.50
p value (preop. to 1 month, preop. to 1 year, 1 month
to 1 year) 0.019, <0.001, N.S.
Refractive components n � 28 n � 32
1-year postop. Sphere, D −0.46 ± 0.65 −1.02 ± 1.51 N.S.
1-year postop. Cylinder, D 1.02 ± 1.51 1.08 ± 0.43 N.S.
CMT n � 21 n � 27
N.S.Preop. CMT (µm) 227 ± 64 214 ± 541-month postop. CMT (µm) 229 ± 61 233 ± 99
1-year postop. CMT (µm) 273 ± 158 229 ± 79
p value (any time interval) N.S.
ECD n � 25 n � 25
N.S.Preop. ECD, number of cells (mm
2) 2043 ± 647 2047 ± 489
1-month postop. ECD, number of cells (mm2) 1721 ± 566 1605 ± 521
1-year postop. ECD, number of cells (mm2) 1512 ± 588 1395 ± 380
p value (preop. to 1-month, preop. to 1-year, 1-
month to 1-year) <0.01, <0.01, N.S.
Continuous variables are presented as means ± standard deviation. n: number; BCDVA: best-corrected distance visual acuity; D: diopter; CMT: central
macular thickness; ECD: endothelial cell density; N.S.: not signiﬁcant, p> 0.05.
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(a)
(b)
Figure 2: Corneal specular microscopy pictures for both groups. (a) On the left, preoperative endothelial cell density (ECD) and on the
right, ECD of the same patient in group A 1 month after surgery. (b) Same sequence in a patient in group B.
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Figure 3: Continued.
Journal of Ophthalmology 5
who underwent PPV and in 8 without PPV. e treatment of
CME included nonsteroidal anti-inammatory eye drops in
seven cases, prednisolone eye drops in one case, and subtenon
injection of steroid in two cases (one was followed by
intravitreal dexamethasone implant a few months later).
Table 2 shows the cumulative incidence of all complications
over 12 months after surgery. Notably, there were no cases of
endophthalmitis, IOL disenclavation, subluxation, or dislo-
cation, while IOL tilting or decentration was reported in four
eyes (three in group A). e incidence of each type of
complication was comparable between the two groups.
Univariate and multivariable stepwise linear regression an-
alyses were performed on the nal BCDVA, which was
predicted most strongly by the BCDVA at 1 month after
surgery. e nal BCDVA did not show an association with
the IOL placement type (anterior vs. retropupillary; Table 4).
4. Discussion
Although some previous studies described using iris-claw
IOL implantations, very few compared the AC and PC
positions [15–17]. e need for a thorough comparison
including variables such as ECD and CMTprompted us to
perform the present study [18], where we assessed long-
term functional and safety outcomes in a large group
of eyes that underwent AC or PC iris-claw IOL implan-
tation. We found that both positions aorded signicant
BCDVA improvement at early (1 month) and long-term
258
292
276
298
298253274237
249
276
319
297
330
356383294247
263
(b)
Figure 3: Optical coherence tomography (OCT) scans of cystoid macular edema (CME). (a) OCT scans of a patient in group A at the
preoperative visit (left) and at the 1-year postoperative visit, when CME was detected. (b) OCTscans of a patient in group B showing normal
foveal thickness at the preoperative visit and CME at the 1-month postoperative visit.
Table 4: Univariate and multivariable regression analysis showing factors inuencing nal BCDVA.
Covariate Interval
Univariate analysis Multivariable analysis
β coe 95% CI β coe 95% CI
Age 1 year increment 0.06 −0.02–0.16 —
Gender Female vs. male 0.32 0.07–0.57 0.14 −0.05–0.34
Iris-claw IOL placement AC vs. PC 0.02 −0.22–0.27 −0.07 −0.26–0.11
Prior trauma Vs. no prior trauma 0.01 −0.08–1.1 —
Previous surgery Vs. no surgery 0.13∗ 0.05–0.20 0.08∗ 0.02–0.14#
Preexistent corneal pathology Vs. no preexistent corneal pathology 0.24 −0.13–0.62 —
Preexistent macular pathology Vs. no preexistent macular pathology 0.68∗ 0.22–1.14 0.21 −0.16–0.59
Preexistent retinal pathology Vs. no preexistent retinal pathology 0.11 −0.15–0.37 —
Postop. CME Vs. no postop. CME 0.07 −0.19–0.35 —
Postop. PBK Vs. no postop. PBK 0.25 −0.12–0.63 —
Postop. complication† Vs. no postop. complications 0.25∗ 0.01–0.49 —
BCDVA at 1 month 0.1 logMAR increment 0.70∗ 0.48–0.92 0.63∗ 0.42–0.84#∗p< 0.05; †  excluded from multivariable model due to variance ination; #  β-coe©cient based on stepwise regression model for best t. R2  0.57; IOL:
intraocular lens; CME: cystoid macular edema; PBK: pseudophakic bullous keratopathy; BCDVA: best-corrected distance visual acuity; AC: anterior
chamber; PC: posterior chamber; CI: condence interval.
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(12 months) follow-ups, with ﬁnal visual and refractive
outcomes being similar between the two groups. Con-
cerning safety, CMT, ECD loss, and type and percentage of
postoperative complications were comparable between the
groups. At the end of follow-up, the CMT was not sig-
niﬁcantly diﬀerent from the preoperative value in either
group, which was consistent with previous studies [11, 12].
We analyzed ECD loss at 1 and 12 months; loss at the ﬁrst
time point is assumed to mainly reﬂect intraoperative
cellular loss, while ECD loss occurring between 1 month
and 12 months is attributable to the presence of the IOL. As
expected, the ECD loss rate at 1 month was approximately
twice that observed thereafter; however, there was no
diﬀerence between the two groups in the ECD loss over
time. In a previous study comparing AC and PC iris-claw
IOLs in combination with PPV, no diﬀerence in ECD loss
was found at 3 months [17]. Conversely, another study in
patients undergoing penetrating keratoplasty, IOL re-
moval, and iris-claw IOL ﬁxation documented a greater
ECD loss between 6 months and 12 months after surgery in
case of AC IOL placement [16]. *e cumulative incidence
of all other recorded postoperative complications was
similar between the two groups although there was a trend
toward a higher proportion of chronic IOP elevation in the
AC versus PC IOL position (p � 0.08). Previous studies
evaluating long-term outcomes of iris-claw IOLs reported
variable postoperative complication rates [7, 8, 10, 11]. To
understand this variability, the surgical procedures per-
formed in conjunction with IOL implantation should be
considered, such as complicated cataract surgery or PPV.
*e relatively high incidence of complication of our groups
was comparable to those in a study evaluating iris-claw IOL
ﬁxation in conjunction with PPV and lens/IOL removal
[17]. Similarly, in our study, the majority of the surgeries
(70%) were performed in combination with lens or con-
ventional IOL removal. *e elder age of our patients might
also have contributed to the increased proportion of
complications.
Multivariable analysis of the whole cohort indicated
that the BCDVA at 1 month predicted the ﬁnal BCDVA
(i.e., that at the 12-month follow-up). Assuming that
variables such as irregular astigmatism, perioperative
complications, and preexistent macular or corneal
anomalies may inﬂuence visual acuity at both 1 and 12
months after surgery, it was expected that good visual
acuity at 1 month would persist to 12 months. Notably, the
majority of the eyes in our study still had corneal sutures
after 1 month. *erefore, we suggest that, for optimal
outcomes, astigmatism control should be ensured during
application of the corneal suture, irrespective of whether an
AC or PC iris-claw IOL is used. *e major weakness of our
study lays in its retrospective design and the consequent
lack of randomization to IOL placement groups or stan-
dardization of data collection.
5. Conclusion
*e present study compared AC and PC iris-claw IOL
implantation outcomes over a 12-month follow-up period.
Our results showed that the procedures were equally ef-
fective and safe for managing cases of aphakia with in-
adequate capsular support. Future studies should include
ultrasound biomicroscopy assessments of the anatomy of
AC and PC structures after implantation. Furthermore, in
cases of posterior luxation of the lens during cataract sur-
gery, primary iris-claw IOL implantation and a two-step
procedure including correction of aphakia at a later and
quieter stage should be compared.
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